StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
PRAXBearishIndustry Newsnews
Medium materiality6/10

Praxis Pauses Vormatrigine POWER2 Enrollment After Mixed POWER1 Results

Jun 1, 2026, 4:23 PM EDT4 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Primary endpoint miss weighs on Vormatrigine's near-term valuation; POWER2 pause may delay potential upside catalysts and raise execution risk, despite a dose signal and decent safety; barometer on overall Praxis pipeline remains mixed until program revisions are announced.

AI summary

What happened, with direct paths to the underlying reporting

Praxis Precision Medicines reported POWER1 results for vormatrigine in focal onset seizures. The primary endpoint was not met, but the higher-dose arm showed a stronger seizure reduction and low discontinuations. Praxis is pausing POWER2 to reassess the program, while continuing focus on relutrigine and ulixacaltamide launches; about 90% of Vormatrigine patients moved to an open-label extension, signaling retention but uncertain path to approval.

  • POWER1 failed primary endpoint in focal onset seizures; higher-dose signal observed.
  • Secondary endpoint: 50% response rate met; 30 mg dose showed stronger seizure reduction.
  • Vormatrigine well-tolerated; adverse-event discontinuations <10%.
  • Approximately 90% transitioned to open-label extension (OLE) and remain in it.
  • Praxis pauses POWER2 enrollment to reassess vormatrigine program and potential modifications.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event